Search
lusutrombopag (Mulpleta)
Indications:
- thrombocytopenia in adults with chronic liver disease scheduled for dental procedure [1]
Contraindications:
- breast feeding not recommended
Dosage:
- 3 mg PO QD with or without food for 7 days
Tablets: 3 mg
Adverse effects:
- headache >= 3% (most common) [1]
Mechanism of action:
- thrombopoietin receptor agonist
General
thrombopoietin receptor agonist
Database Correlations
PUBCHEM cid=49843517
References
- FDA Approved Drugs. July 31, 2018
FDA approves lusutrombopag for thrombocytopenia in adults with
chronic liver disease.
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615348.htm
- HIGHLIGHTS OF PRESCRIBING INFORMATION
MULPLETA (lusutrombopag tablets) for oral use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf